The company’s REGENERA™/SOFTAG™ biomaterial offers a regenerative alternative to traditional post-lumpectomy reconstruction. Designed as an off-the-shelf solution, the implant provides a framework for healthy tissue regrowth after tumor removal. Unlike permanent artificial devices, the material gradually dissolves, allowing the patient’s own tissue to restore the breast's natural shape. Surgeons can utilize a minimally invasive procedure, potentially sparing patients from more complex reconstructive surgeries.
Beyond tissue regeneration, the implant features high visibility during diagnostic imaging. This clarity allows medical teams to target radiotherapy with greater precision and improves the accuracy of follow-up examinations. EIB Vice President Gelsomina Vigliotti highlighted the investment as a strategic move to address underserved gaps in women’s health technology.
Securing this capital provides Tensive a vital financial runway to navigate the demanding regulatory environment and costly clinical validation required for medical devices. CEO Sanjay Kakkar noted that the bank’s commitment follows a rigorous review of the company’s recent pivotal clinical data. With this support, Tensive aims to transition its technology from the laboratory to routine clinical practice across Europe, strengthening the continent's domestic medical research and manufacturing capabilities.
Comments (0)
No comments yet. Be the first!